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Abstract
Background: Microarray data preprocessing, such as differentially expressed (DE) genes selection, is performed
prior to higher level statistical analysis in order to account for technical variability. Preprocessing for the
Affymetrix GeneChip includes background correction, normalisation and summarisation. Numerous preprocessing
methods have been proposed with little consensus as to which is the most suitable. Furthermore, due to poor
concordance among results from cross-platform analyses, protocols are being developed to enable cross-platform
reproducibility. However, the effect of data analysis on a single platform is still unknown. The objective of our
1
study is two-fold: first to determine whether there is consistency in the results obtained from a single platform;
and second to investigate the effect of preprocessing on DE genes selection, analysed on four datasets.
Results: Results indicate that microarray analysis is subjective. The lists of DE genes are variable and dependent
on the preprocessing method used. Furthermore, the characteristics of the dataset, and the type of DE genes
identification method used, greatly affect the outcome. Despite using a single platform, there is a lot of
variability in the results.
Conclusions: This is the first comprehensive analysis using multiple datasets generated from a single platform
and involving many DE genes selection methods to assess the effect of data preprocessing on downstream
analysis. Results indicate that preprocessing methods affect downstream analysis. Results are also affected by
the kind of data and statistical analysis tools used. Our study reveals that there are inconsistencies in results
obtained from a single platform. These issues have been overlooked in past reports.
Background
Since its invention in 1995 [1], microarray technology has become a principal tool for high-throughput gene
expression detection and analysis in basic science research and clinical studies. A simple search on PubMed
will return over 10,000 papers on microarray analysis published within the last two years. A plethora of
gene expression data on model systems and human diseases has been collected and organised at NCBI and
many other microarray data repositories. Large microarray data have been produced by many different
microarray platforms, including the widely used Affymetrix GeneChip [2].
Concomitant with the production of massive amounts of data, there has been a proliferation of
computational methods for quantifying the level of expression on a DNA chip for various microarray
platforms. Even with the same microarray platform, the quality of microarray gene expression can also be
significantly impacted by the data preprocessing methods adopted. Several studies have called into question
the validity of microarray results mainly due to the disparities between results obtained by different groups
analysing similar samples [3–5]. Therefore, efforts have been directed to the understanding of the causes of
discrepancies across platforms and the development of protocols that would allow for cross-platform
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comparisons and reproducibility [6–8]. Unfortunately, the effect of data preprocessing methods, even for
the same microarray platform, has not been well understood nor adequately addressed so far.
An important aspect of our investigation is that, although we used multiple datasets, we focused on data
generated from a single platform. Hence, one of the main objectives of this paper is to provide the first
comprehensive analysis of data preprocessing methods on the same microarray platform. By focusing on
one microarray platform, we are able to avoid complications from cross-platform gene expression detection
and minimise the variability in the results. Furthermore, if there is a huge discrepancy despite using a
single platform, then there will be even greater disparities in a cross-platform study.
Along with the increased use of microarray technology, preprocessing methodology for Affymetrix
GeneChip – the market leader – is a quickly expanding research subject. In order to compare preprocessing
methods, the affycomp webtool [9] was established in 2003, where over 40 microarray preprocessing
methods have been submitted by users [10]. In our study, we focused on the Affymetrix GeneChip platform
because it is widely used and a large number of data preprocessing methods has been developed for it.
Gene expression measurements are confounded by different sources of systematic variation. Sources of
noise include differences in dye efficiencies, scanner malfunction, uneven hybridisation, array design,
experimenter and other extraneous factors. In order to compare the mRNA expression levels of each probe
on a microarray chip as well as compare microarrays from different experiments for the purposes of
performing higher-order analyses such as clustering, prediction, and building regulatory networks, it is
necessary to remove unwanted variations while retaining intrinsic biological variations. Thus, data
preprocessing is a critical step that affects accuracy and validity of downstream analyses. The four main
preprocessing steps for Affymetrix GeneChip are - background correction, normalisation, perfect match
(PM) probe correction and summarisation. New processing algorithms that claim to handle the
characteristics of microarrays well, are continuously being developed. However, there still is no consensus
on which processing method is the most efficient [11,12] or how a preprocessing method be chosen.
Differentially expressed (DE) gene ranking or selection is the next course of action after data generation.
The use of microarrays to determine bona fide changes in gene expression between experimental paradigms
is confounded by noise due to variability in measurement. Since scientists are eager to use microarrays to
identify marker genes and understand the pathogenesis of diseases, there should be an acute awareness of
what procedures are being used to identify the molecular signature of a phenotype. Therefore, the second
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objective of our analysis is to assess the variability in measurement by investigating the effect of different
background correction, normalisation, PM correction and summarisation techniques on downstream
analysis, in particular, DE gene selection. Most literature on comparison of microarray processing methods
usually analyse either background correction or normalisation. Furthermore, not only do these studies
focus on just one dataset, they use tightly controlled calibration data derived from spike-in or dilution
studies [10,13,14] or data from very simple organisms [15]. However, to date, we have not found any
literature that has thoroughly examined the influence of each of these preprocessing stages on DE gene
selection on multiple, diverse, real-life datasets. If the DE gene selection stage is highly affected by these
preprocessing mechanisms, all subsequent stages will also be affected.
Based on biological assumptions and microarray chip design, many types of preprocessing algorithms have
been developed to date [16,17]. Background correction is the process of correcting probe intensities on an
array using information only from that array. Normalisation is the process of removing non-biological
variability across arrays. Summarisation is the process of combining the preprocessed PM probes to
compute an expression measure for each probeset on the array. In our paper, we focus on the two most
widely used preprocessing pipelines, Microarray Suite 5.0 (MAS5.0, now GeneChip Operating System -
GCOS) developed by Affymetrix [18], and Robust Multiarray Analysis (RMA) [14]. We used RMA and
MAS5.0 for background correction, and constant normalisation and quantile normalisation [14] methods,
for normalisation. MAS5.0 and RMA were applied for PM correction, while MAS5.0 (Tukey Biweight) and
RMA (medianpolish) were employed for summarisation. Since GC - Robust Multichip Average
(GCRMA) [19] is a popular method for background correction and many consider it as one of the best
current preprocessing methods [10,20], we conclude our study with the application of this technique.
The gene selection tools investigated in this study were extraction of differential gene expression
(EDGE) [21] and RankGene [22]. These two packages were chosen mainly due to their widespread usage.
At a false discovery rate level of 3%, EDGE provides a 198% increase over the highly popular SAM
software [21] and therefore, was preferred, in our study, over SAM. Finally, we want to verify whether the
choice of a preprocessing method has a greater effect on gene selection than the choice of gene selection
tool, which was the conclusion reached by [23].
Following is a brief overview of the study. Four diverse, non-time series, human datasets generated from
Affymetrix DNA chip were used in this study - Alzheimer’s disease (AD) [24], breast cancer [25], Duchenne
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muscular dystrophy (DMD) [26] and chronic myelogenous leukemia (CML) [27]. These particular datasets
were chosen since they capture intrinsic gene expression variations underlying these diverse human
diseases, and they have as large a number of samples as one can expect from clinical experiments. On each
of the four different datasets we applied sixteen different preprocessing strategies resulting from the
combining all possible combinations - two for each of the four stages of data preprocessing. In addition,
four strategies with GCRMA at the background correction stage were also applied (see Table1). A set of
processing methods for each stage, for example, RMA (R) for background correction, constant (C) for
normalisation, MAS 5.0 (M) for PM correction and RMA (R) for summarisation refers to a ‘combination’.
The order of data preprocessing is first background correction, then normalisation, followed by PM
correction, and finally summarisation. The four letters in each combination refer to the methods used in
the four preprocessing stages in order. R refers to RMA, C refers to constant, Q refers to quantile, M refers
to MAS5.0, and G refers to GCRMA. DE gene selection using EDGE as well as RankGene was performed
on each combination. In order to determine which method had the greatest effect on DE gene selection,
comparisons were made between combinations which differed in a method for a single stage, for example,
between RCMR and RCRR (method for PM correction differs). Number of common transcripts was used
as the measure of similarity between methods. If the methods are highly dissimilar, then the number of
overlapping transcripts would be small. The results have been presented as graphs representing the number
of overlapping transcripts as well as via hierarchical clustering.
Results
Combinations were divided into seven groups/sets of four comparisons - one comparison for each of the
four processing stages. The results are presented as bar graphs representing the number of overlapping
transcripts. Each bar represents one comparison between two combinations. All the graphs have seven sets
of four bars (excluding the last group on the far right of each graph). In any particular set, in each of the
comparisons, only one of the four preprocessing methods is changed. In any graph, the heights of the bars
should be compared within the set of four comparisons (i.e. one group) and not across the whole graph.
Greater the effect of the method, smaller will be the number of common transcripts between the two
preprocessing combinations, implying greater dissimilarity between the combinations. Figures 1-20 show
the amount of overlap between any two combinations in each of the four datasets. In RankGene, for each
combination, 500 transcripts were ranked according to the ranking criteria of choice. In EDGE, the
5
number of significant transcripts were chosen based on the p value. In the case of EDGE selected
transcripts, the total number of transcripts was different in each combination as can be seen in Table 1.
Therefore, in order to compare the degree of overlap of two combinations, the arithmetic mean between the
two combinations is computed. Therefore, the graphs on EDGE have the mean on the y-axis. Again, the
bar with the smallest mean indicates the greatest dissimilarity between the two combinations. Heatmaps of
the different comparisons were generated on each dataset with the EDGE selected transcripts (figures
21-24) to determine if there was any discernable pattern. All the probe lists obtained from different
combinations and different gene selection/ranking methods are included as additional data files.
Table 2 shows the number of significant transcripts using EDGE only. Results indicate that preprocessing
technique has a greater effect on gene selection than the kind of gene selection methods used. For example,
if the number of significant transcripts in RCRR and RQRR is compared, the huge difference in the
number of transcripts can easily be observed, despite using the same gene selection method.
The relative difference in the heights of the bars in the graphs is phenomenal across datasets for the same
gene selection method. From figures 16-20, one can observe that the preprocessing methods have a greater
similarity when applied to the DMD dataset. However, there is a lot of disparity among the preprocessing
combinations when applied to the AD dataset. This clearly indicates that the characteristics of datasets,
i.e. the amount of variability in gene expression, have an effect on the preprocessing method. If any one
comparison is analysed across all datasets for any one gene selection method, for example, if the height of
the MCMM-RCMM bar is observed across the different datasets, the bar height varies across datasets.
This indicates that the effect of a preprocessing technique also depends on the kind of dataset. However,
the same comparison across different gene selection methods on the same dataset does not produce a
drastic difference in the result. These observations along with the results in Table 2 indicate that the
preprocessing techniques play a greater role on DE gene selection than the gene selection method applied,
whether it be RankGene or EDGE. This confirms the conclusion attained by [23].
On any dataset, the method that has the maximum effect varies across different gene selection techniques.
Only in the breast cancer dataset, it seems that normalisation has the greatest impact. However, since the
stage depends on the kind of technique used in that stage, we cannot reach any definitive conclusion about
whether it is the stage or the technique that has the greatest effect. Analysis of this is left for future
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research.
Bar graphs were not created for all possible comparisons between combinations due to lack of space.
Therefore, hierarchical clustering was performed primarily to enable visualisation of comparisons between
all pairs of combinations. Pattern detection is easier via clustering. However, as can be seen from figures
21-24, the hierarchical clustering does not show any definite pattern with respect to the preprocessing
techniques.
Initially we had only applied RMA and MAS5.0 for background correction. When no conclusive results
surfaced, we applied the GCRMA method. As GCRMA has grown in popularity, we presumed that it
would eliminate the discrepancies observed in the results thus far in our study. However, as can be
observed from figures 1-24, GCRMA did not help in resolving matters. GCRMA and RMA belong to the
same family of processing methods. However, if GCRM and RCRM or GQRM and RQRM is compared,
the number of overlapping transcripts is sometimes high, as in the case of the breast cancer dataset,
sometimes low, as in the case of the AD dataset, and sometimes there is no overlap at all, as in the case of
the CML dataset. This is also true for all the other comparisons involving GCRMA. In all the bar graphs,
the far right end consists of comparisons between GCRMA, RMA and MAS5. Again, there does not seem
to be any consistency in the results obtained after applying GCRMA. Results tend to be variable
depending on the data analysed and the DE gene selection method employed.
Discussion
Our study is the first systematic and comprehensive analysis of the effect of all the data preprocessing
stages on DE gene selection analysed on multiple human datasets. There are three key conclusions from
this study. The first is that different preprocessing techniques have varying degrees of effect on downstream
analysis based on the kind of data analysed. Preprocessing techniques are not robust enough to handle the
amount of variability contained in microarray data. Second, the choice of gene selection methods used to
evaluate the effect of preprocessing, also affects the outcome. Third, even with using a single platform, the
discrepancies between results are substantial.
It is a cause for great concern if the results from the same dataset, using the same gene selection tool on
the same platform are not more in concordance. This implies that preprocessing methods have a great
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impact on statistical analyses and this in turn affects the reproducibility of results. If there is little or no
consensus among results from the same platform, cross-platform discrepancies cannot be effectively
surmounted. Therefore, efforts should be directed towards methods that would increase consistency among
results generated from the same platform before extending them to cross-platform analysis. Only statistical
analysis techniques and inter-laboratory experiment protocols are not the causes of cross-platform
disparities as mentioned by [6,7]. Along with standardising research protocols and statistical analysis tools,
attention should be paid to data preprocessing methods.
Some reports state that background correction or normalisation have the greatest effect [10,23,28] on DE
gene selection. As there are no standard evaluation methods, different reports can provide conflicting
results. Investigators evaluating processing methods should also address data quality and assessment tools
used. Recently, there has been a deluge of research articles, editorials and commentaries on the reliability
of microarray results [29–32]. Ioannidis [29] goes so far as to say that given information on a gene and 200
patients, he can show that this gene affects survival (p < 0.05) even if it does not! Due to poor accuracy,
sensitivity, specificity and reproducibility, microarrays have not yet passed the Food and Drug
Administration (FDA) regulations for routine use in clinical settings.
Miklos and Maleszka [3] state that different analyses of the same microarray data lead to different gene
prioritisations. Another group performed a multiple random validation strategy to re-analyse data from 7
of the largest microarray studies to identify a molecular signature of cancer, and discovered that molecular
signatures are unstable [33]. Disparities between genes selected from microarray analysis and biologically
relevant genes (i.e. those that are truly relevant) are great even on simple organisms such as yeast [34].
Hence, the incongruity cannot be a characteristic of complex multi-cellular organisms. On the other hand
many studies claim that their list of genes is significant based on p value, which is typically less than 0.05.
However, statistical significance does not imply biological significance. Due to this emotional dependence
on p values, the majority of the published results may be irrelevant if not false [35,36].
This study, along with results in other reports, indicates that microarray analysis is subjective and highly
unstable. So how can these problems be overcome? Just developing new algorithms for data preprocessing,
without addressing the reasons why the currents methods fail, will not solve the problems related to
microarray analysis. No matter how sophisticated higher analyses become, one cannot ignore the fact that
microarray chip design also needs to be improved. The correct design of probes on a DNA chip is essential.
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Additionally, due to cross-platform and inter-laboratory discrepancies, one should be wary of generating or
accepting results derived from meta-analysis data. Furthermore, evaluation of bioinformatics protocols
should be done on real-life datasets in addition to the well-controlled, calibration datasets. Most of the
previous work on the analysis of processing algorithms was performed on the dilution or spike-in data from
Affymetrix [10,13,14]. However, the variance of the average chip intensity in such data is much lower than
those measured in real-life, and not well-controlled, datasets. Furthermore, the use of a limited number of
spike-in genes is not sufficient for a comprehensive analysis of both microarray technology and data
analysis methods. Such issues with spike-in data will cast doubts on the applicability of such data for the
development of analytical tools for use in diverse gene expression profiles. Large sample size is crucial.
Although it is expensive and time consuming to gather a large number of samples, it is the price one has to
pay for accuracy and reproducibility. It is also essential to understand the limitations of the technology
being used. One thing the current microarray technology is still unable to deal with is the reliable detection
of transcripts with low expression. Therefore, attempting to do this without improved technology is
inadvisable. Characteristics of high-throughput data need to be well understood and addressed accordingly
in the design and execution of experiments. Miron and Nadon [31] term this as ‘inferential literacy’.
Previous studies have indicated that the high rates of irreproducible results are due to research findings
being defended only by statistical significance. Hence, the use and development of other methods of
analysis, such as the one suggested by [37], should be encouraged. Avoidance of bias in the manipulation of
the analyses as well as having clear study designs will help scientists who plan on embarking onto the field
of microarray analysis and prevent them from performing experiments that would most likely erroneous.
In conclusion, efforts should be directed to (i) improved chip design, (ii) ‘inferential literacy’, (iii) large
sample sizes, (iv) random sampling of data for validation, (v) evaluation of tools on real-life as well as
calibration datasets, (vi) multiple and completely independent validation of results, (vii) standardisation of
evaluation techniques and laboratory protocols, and finally (viii) application of better methods of
significance analysis. The good news is that a fraction of the scientific community is realising the problems
surrounding microarray analysis and appropriately addressing these issues. However, it will be a while
before everyone understands and utilises the fruits of this labour.
Microarray technology is indeed a valuable tool. However, it is important to minimise and separate noise
from meaningful information in the data by employing proper experiment and data analysis protocols.
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Processing of noise masquerading as knowledge or eliminating valuable information while removing noise,
will lead to faulty or overoptimistic conclusions. In the absence of proper evaluation tools and standardised
experiment procedures, microarray analysis has become more of an art than science; more like an act of
faith than scientific inference. There is an elephant in the room.
Materials and Methods
Data
For the purpose of generalising results, we make use of four datasets, all of which were generated from
Affymetrix DNA chip. The first is Alzheimer’s Disease (AD) data, generated on Affymetrix GeneChip
(HG-U133A) by [24]. The dataset consists of 9 controls and 22 affected individuals. The affected
individuals had varying degrees of AD severity ranging from incipient to severe. In our analysis, we
compared the nine controls versus the seven incipient cases. The second dataset is on breast cancer,
generated from Affymetrix GeneChip (HG-U95A)and initially analysed in [25] and [38]. Breast cancer core
biopsies were taken from patients found to be resistant or sensitive to docetaxel treatment. The data
consists of 24 tumour samples, 10 of which are sensitive to docetaxel and 14 of which are resistant to
docetaxel treatment. The third dataset is on Duchenne muscular dystrophy (DMD), generated from
Affymetrix GeneChip (HG-U95A) and analysed in [26]. In this dataset, quadricep skeletal muscle biopsies
were taken from 12 DMD patients and 12 unaffected control patients. The fourth dataset is on the
response of chronic myelogenous leukemia (CML) patients to imatinib (Gleevec) treatment, produced from
Affymetrix GeneChip (HG-U95A) and analysed in [27]. All four datasets are available to the public on
PubMed. AD data can be directly downloaded from [39], breast cancer data from [40], CML data from [41]
and DMD data from [42].
Data Preprocessing
Computation of gene expression measure is a four step procedure - background correction, normalisation,
perfect match (PM) probe correction and finally summarisation. In most cases, PM and summarisation are
combined into one step. Let X be the raw probe intensities across all arrays and E be the final probeset
expression measures. Then if B is the background correction operation on probes on each array, N is the
operation which normalises across arrays and S is the operation that combines probes to compute an
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expression measure, the gene expression measure can be formulated as [28]-
E = S(N(B(X))) (1)
Twenty different combinations of background correction methods, normalisation methods, PM correction
methods and summarisation methods were considered to determine which method has the greatest effect
on gene selection.
Background Correction
For the purposes of our analysis, we used the RMA, GCRMA and MAS5.0 background correction methods.
MAS 5.0 Background Correction: This method was developed by Affymetrix [18]. Briefly, each chip is split
up into 16 zones of equal size. For each zone k, the background bk and the noise nk are defined as the
mean and standard deviation of the lowest 2% of zone k’s probe intensities, respectively. The probe specific
background value b(x, y) and noise value n(x, y) are defined as a weighted sum over all bk and nk,
respectively, where x and y denote the position of a probe on the chip. The corrected signal is the raw
signal reduced by b(x, y) where physically possible, otherwise it is n(x, y). Please refer to [18] for more
details.
RMA Background Correction: Robust Multi-array Average (RMA) is a widely used alternative
preprocessing strategy for Affymetrix GeneChips [14]. The procedure is based on the assumption that the
observed probe signal O consists of a normally distributed background component N and an exponentially
distributed signal component S such that
O = N + S, N ∼ N(µ, σ2), S ∼ Exp(α) (2)
The parameters α, µ, and σ2 are estimated from the data, and the raw intensities are replaced with the
estimated expected value Eˆ(S|O = o) given the observed value o.
GCRMA Background Correction: GCRMA is a further development of RMA that takes the probe specific
hybridisation affinities into account [19]. It also acknowledges the use of mismatch (MM) probes (see
below). The following model is fitted (where PM refers to perfect match probe) -
PM = OPM +NPM + S
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MM = OMM +NMM + φS (3)
where OPM and OMM represent optical noise, NPM and NMM represent non-specific binding noise, and S
is the actual signal of interest. φ is a value between zero and one and accounts for the fact that MM probes
tend be less sensitive than their corresponding PM probes but often still measure a specific signal. The
parameters NPM and NMM are assumed to be a function of the probe specific hybridisation affinity which
is pre-computed based on either a calibration data set or the experimental data – in our study we choose
the latter. Equation (3) is then fitted using an empirical Bayes approach. Please refer to [19] for more
details.
Normalisation
For the purposes of our analysis, we used constant or global normalisation and quantiles normalisation.
The former is similar to the one used by Affymetrix, the latter is part of the RMA preprocessing strategy.
Global Normalisation: The term “global normalisation” refers to a family of methods where each probe
intensity is scaled by a chip-specific factor such that a given summary statistic m′j is equal for all chips
after scaling. That is m′j = m, for j = 1, . . . , J , where J is the number of samples. Commonly used
summary statistics include sum, median, and mean. In global normalisation, the mean of the first sample
is used (without loss of generality), m = m1. Thus, the chip specific scaling factor is computed as follows-
fi =
m1
mj
, j = 1, . . . , J, (4)
where mj is the mean of all probe intensities in sample j.
Quantiles Normalisation: Quantiles normalisation assumes that the intensities of each chip originate from
the same underlying distribution. That is, the quantiles for each chip should be the same. However, biases
in the signal generating process result in chip-specific distributions. The goal of quantiles normalisation is
to remove these biases by transforming the data such that each quantile is the same across all chips. Based
on this rationale, the following algorithm was proposed [14].
• Sort probe intensities Xj for each sample j.
• For each quantile (or rank) i, compute the mean mi =
1
J
∑
j x(i)j .
• Replace x(i)j by mi for each sample j.
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• Restore the original order of Xj for each sample j.
Perfect Match Correction
Each perfect match (PM) probe on an Affymetrix GeneChip is complemented by a mismatch (MM) probe
which has a different base as its 13th nucleotide. Hence, a mismatch probe is identical to the perfect match
sequence except for a single incorrect base in the middle of the oligomer. The rationale for including MM
probes in the chip design is to provide a tool for measuring the unspecific binding contribution of the
signal. In our study, we applied the MAS5.0 and RMA PM correction methods. The MAS5.0 PM
correction is performed as follows. First, compute the ideal mismatch IMij for each probe pair i in each
sample j and then subtract IMij from the PM probe intensity PMij , where the ideal mismatch is equal to
the mismatch probe intensity MMij , if MMij < PMij , otherwise IMij is computed by downscaling the
corresponding perfect match signal. Please refer to [18] for more details. In RMA preprocessing, mismatch
probes are simply ignored due to the fact that these probe signals also have probe-specific signal
contributions, which would dilute the PM corrected signal.
Summarisation
Affymetrix DNA microarrays contain multiple probes for each target transcript. In order to establish a
single expression value for each probeset (i.e. a set of probes corresponding to the same transcript),
individual probe values must be summarised. Affymetrix provides chip definition files (CDFs) which can be
used to determine probeset assignments. However, recent studies suggest that the manufacturer’s probe
design and annotation may be outdated and erroneous [43]. Therefore, redefined CDFs (version 6,
reference database: RefSeq) were obtained from [44] and used instead of the manufacturer’s CDFs. For the
purposes of our analysis, we used the MAS5 (“Tukey Biweight”) and RMA (“medianpolish”)
summarisation methods.
Tukey Biweight : This algorithm is described in [18] in detail. Briefly, probe values are log-transformed
after PM correction. Next, for each probeset,
1. For each probe j, the deviation uj from the median weighted by the median deviation from the
median is computed.
2. For each probe j, the weight wj = (1− u
2)2 is computed.
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3. The weighted mean TBI is computed where
TBI =
∑
j wjxj∑
j wj
(5)
TBI is the final summary value.
Medianpolish: This algorithm is used as part of the RMA framework [14]. Briefly, a two-way ANOVA-like
model is fitted:
log2(yij) = αi + µj + ǫij , (6)
where αi is the probe affinity effect of probe i,
∑
i αi = 0, µj represents the expression level for array j,
and ǫij is an independent identically distributed error term with zero mean. The estimate µˆj is the wanted
expression value for the respective probe set on array j. The model parameters are estimated using a
robust procedure that iteratively estimates the error matrix ǫˆij by repeatedly subtracting row medians and
column medians in an alternating fashion until reaching convergence.
Clustering
For a given gene selection method twenty gene lists were obtained, one for each preprocessing combination.
Next, a 20× 20 similarity matrix was computed by counting the number of common genes for each pair of
strategies. In case of EDGE, this number was normalized by 12
(
1
l1
+ 1
l2
)
where l1 and l2 are the lengths of
the first and second gene list, respectively, in order to account for the varying lengths of significantly
changed gene expression generated by each preprocessing strategy. The similarity matrix S was then
converted to a distance matrix D by subtracting S from the maximum value m of S, D = m− S. Next,
hierarchical clustering based on D was computed using function hclust() of the statistical package R [45].
Briefly, this function initially assigns each preprocessing method its own cluster. Next, the algorithm
iteratively combines the two most similar clusters until the all-cluster is formed comprising all
preprocessing methods. After each joining of two clusters, cluster distances are recomputed using the
Lance-Williams dissimilarity update formula. In our implementation, we use complete linkage, i.e. the
distance between the most dissimilar pair of preprocessing methods, one from each of the joining clusters.
The clustering was then combined with a heatmap using the R function heatmap() on S such that red
indicates high similarity and white indicates no similarity.
14
Differentially Expressed Gene Identification
Significant gene identification or selection of differentially expressed (DE) genes has been a subject of
active research for many years, resulting in a multitude of algorithms. Significant gene extraction falls into
two broad categories - wrapper methods and filter methods. In wrapper gene selection methods, the DE
gene identification phase is integrated with the classification phase. The main objective of such an
algorithm is to find a gene subset that will result in the highest classification accuracy. In filter methods,
the DE gene extraction phase is independent of the classification phase. After significant gene selection,
one can use any classifier on that subset of genes and tune the model to achieve high accuracy.
Wrapper methods attempt to remove redundancy and irrelevancy in the list of significant features/genes.
However, if the objective is to identify new genes responsible for a phenotype, then redundancy should not
be eliminated. In the process of eliminating redundant genes, one can lose a potentially new marker gene.
Since our study focused on concept discovery, where the objective is to discover new genes, we only
considered filter methods. Most of the previous studies on preprocessing techniques used filter methods,
such as ANOVA and the ratio of expression levels, to obtain a list of DE genes. In this study, we used two
packages for the identification of DE genes - RankGene [22] and EDGE [21].
RankGene is a C++ programme for analysing gene expression data, feature selection and ranking genes
based on the predictive power of each gene to classify samples into functional or disease categories [22]. It
supports eight measures for quantifying a gene’s ability to distinguish between classes: information gain,
twoing rule, sum minority, max minority, Gini index, sum of variances, t-statistics, and one-dimensional
support vector machines. The first six of the eight methods are quite commonly used statistical learning
techniques. One-dimensional SVM measures the effectiveness of a gene by calculating the accuracy of
single feature SVM classifiers. The t-statistics measure was first used in [46] and is a commonly used
technique. Since we are not evaluating different gene selection methods but rather investigating the effect
of preprocessing on DE gene selection strategies, which gene selection technique we use is of little concern.
In our analysis, we used information gain, twoing rule, t-statistic and sum minority. Information gain,
twoing rule, and sum minority are statistical impurity measures, which quantify the best possible class
predictability that can be obtained by dividing the full range of expression of a given gene into two disjoint
intervals. All samples in one interval belong to one class (e.g, normal) and all samples in the other interval
belong to the other class (e.g, affected). The difference among the various measures is used to quantify the
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error in prediction. For a given choice of measure, RankGene minimises the error over all possible
thresholds that partition the gene into two intervals.
EDGE is an open-source software programme which identifies DE genes based on the optimal discovery
procedure (ODP) [21]. It maximises the expected number of true positives for each fixed level of expected
false positives. While most gene selection methods consider only one feature at a time, the ODP method
uses information from the entire data set when testing each feature, which is its greatest asset. It uses a
modified t-statistic to select significant genes. EDGE ranks all the genes in the dataset but also selects a
subset of genes considered significant at a particular p value. EDGE is a newer tool compared to
RankGene and its main advantage is the ability to analyse time series data. The t-statistic of RankGene is
different from that of EDGE. The modified t-statistic of EDGE does not analyse each gene individually for
its significance, but rather takes into account the correlation among different genes.
While EDGE is a gene selection as well as gene ranking tool, RankGene is only a ranking tool. However,
we chose to analyse the top 500 transcripts from the ranked list. By choosing these different gene selection
packages for analysis in this paper, majority of the spectrum of possible filter methods available for gene
selection is covered. By utilising these two DE gene identification softwares, we have applied five different
gene selection algorithms.
List of abbreviations
• DE - differentially expressed
• PM - perfect match
• MAS5.0 - Microarray Suite 5.0
• RMA - Robust Multiarray Analysis
• GCRMA - GC - Robust Multichip Average
• EDGE - extraction of differential gene expression
• SAM - significance analysis of microarrays
• AD - Alzheimer’s disease
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• DMD - Duchenne muscular dystrophy
• CML - chronic myelogenous leukemia
• FDA - Food and Drug Administration
• MM - mismatch
• IM - ideal mismatch
• CDFs - chip definition files
• D - distance matrix
• S - similarity matrix
• ANOVA - analysis of variance between groups
• SVM - support vector machines
• ODP - optimal discovery procedure
• RCRR - RMA background correction, constant normalisation, RMA PM correction, RMA
summarisation
• RQRR - RMA background correction, quantile normalisation, RMA PM correction, RMA
summarisation
• MQRR - MAS5.0 background correction, quantile normalisation, RMA PM correction, RMA
summarisation
• RQMM - RMA background correction, quantile normalisation, MAS5.0 PM correction, MAS5.0
summarisation
• MCMM - MAS5.0 background correction, constant normalisation, MAS5.0 PM correction, MAS5.0
summarisation
• RCMM - RMA background correction, constant normalisation, MAS5.0 PM correction, MAS5.0
summarisation
• MCRR - MAS5.0 background correction, constant normalisation, RMA PM correction, RMA
summarisation
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• MQMM - MAS5.0 background correction, quantile normalisation, MAS5.0 PM correction, MAS5.0
summarisation
• RCRM - RMA background correction, constant normalisation, RMA PM correction, MAS5.0
summarisation
• RQRM - RMA background correction, quantile normalisation, RMA PM correction, MAS5.0
summarisation
• MQRM - MAS5.0 background correction, quantile normalisation, RMA PM correction, MAS5.0
summarisation
• RQMR - RMA background correction, quantile normalisation, MAS5.0 PM correction, RMA
summarisation
• MCMR - MAS5.0 background correction, constant normalisation, MAS5.0 PM correction, RMA
summarisation
• RCMR - RMA background correction, constant normalisation, MAS5.0 PM correction, RMA
summarisation
• MCRM - MAS5.0 background correction, constant normalisation, RMA PM correction, MAS5.0
summarisation
• MQMR - MAS5.0 background correction, quantile normalisation, MAS5.0 PM correction, RMA
summarisation
• GCRM - GCRMA background correction, constant normalisation, RMA PM correction, MAS5.0
summarisation
• GCRR - GCRMA background correction, constant normalisation, RMA PM correction, RMA
summarisation
• GQRM - GCRMA background correction, quantile normalisation, RMA PM correction, MAS5.0
summarisation
• GQRR - GCRMA background correction, quantile normalisation, RMA PM correction, RMA
summarisation
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Additional Files
Additional file 1 — adedge.zip
This file contains the list of transcripts obtained by using EDGE on the AD dataset. Although all the
transcripts are ranked, the number of significant transcripts at a particular cut-off value of p is mentioned
at the top of the file. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 2 — adrankcriteria1.zip
This file contains the list of transcripts, from the AD data, ranked according to RankGene criteria 1 -
information gain. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 3 — adrankcriteria2.zip
This file contains the list of transcripts, from the AD data, ranked according to RankGene criteria 2 -
twoing rule. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 4 — adrankcriteria3.zip
This file contains the list of transcripts, from the AD data, ranked according to RankGene criteria 3 - sum
minority. Each file is named with the preprocessing combination employed on the data. The nomenclature
is explained in background section, last paragraph. Individual files (.txt extension) can be viewed with
Microsoft Excel or Windows Notepad.
Additional file 5 — adrankcriteria7.zip
This file contains the list of transcripts, from the AD data, ranked according to RankGene criteria 7 -
t-statistic. Each file is named with the preprocessing combination employed on the data. The
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nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 6 — bcedge.zip
This file contains the list of transcripts obtained by using EDGE on the breast cancer dataset. Although
all the transcripts are ranked, the number of significant transcripts at a particular cut-off value of p is
mentioned at the top of the file. Each file is named with the preprocessing combination employed on the
data. The nomenclature is explained in background section, last paragraph. Individual files (.txt
extension) can be viewed with Microsoft Excel or Windows Notepad.
Additional file 7 — bcrankcriteria1.zip
This file contains the list of transcripts, from the breast cancer data, ranked according to RankGene
criteria 1 - information gain. Each file is named with the preprocessing combination employed on the data.
The nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can
be viewed with Microsoft Excel or Windows Notepad.
Additional file 8 — bcrankcriteria2.zip
This file contains the list of transcripts, from the breast cancer data, ranked according to RankGene
criteria 2 - twoing rule. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 9 — bcrankcriteria3.zip
This file contains the list of transcripts, from the breast cancer data, ranked according to RankGene
criteria 3 - sum minority. Each file is named with the preprocessing combination employed on the data.
The nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can
be viewed with Microsoft Excel or Windows Notepad.
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Additional file 10 — bcrankcriteria7.zip
This file contains the list of transcripts, from the breast cancer data, ranked according to RankGene
criteria 7 - t-statistic. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 11 — cmledge.zip
This file contains the list of transcripts obtained by using EDGE on the CML dataset. Although all the
transcripts are ranked, the number of significant transcripts at a particular cut-off value of p is mentioned
at the top of the file. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 12 — cmlrankcriteria1.zip
This file contains the list of transcripts, from the CML data, ranked according to RankGene criteria 1 -
information gain. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 13 — cmlrankcriteria2.zip
This file contains the list of transcripts, from the CML data, ranked according to RankGene criteria 2 -
twoing rule. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 14 — cmlrankcriteria3.zip
This file contains the list of transcripts, from the CML data, ranked according to RankGene criteria 3 -
sum minority. Each file is named with the preprocessing combination employed on the data. The
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nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 15 — cmlrankcriteria7.zip
This file contains the list of transcripts, from the CML data, ranked according to RankGene criteria 7 -
t-statistic. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 16 — dmdedge.zip
This file contains the list of transcripts obtained by using EDGE on the DMD dataset. Although all the
transcripts are ranked, the number of significant transcripts at a particular cut-off value of p is mentioned
at the top of the file. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 17 — dmdrankcriteria1.zip
This file contains the list of transcripts, from the DMD data, ranked according to RankGene criteria 1 -
information gain. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 18 — dmdrankcriteria2.zip
This file contains the list of transcripts, from the DMD data, ranked according to RankGene criteria 2 -
twoing rule. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
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Additional file 19 — dmdrankcriteria3.zip
This file contains the list of transcripts, from the DMD data, ranked according to RankGene criteria 3 -
sum minority. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
Additional file 20 — dmdrankcriteria7.zip
This file contains the list of transcripts, from the DMD data, ranked according to RankGene criteria 7 -
t-statistic. Each file is named with the preprocessing combination employed on the data. The
nomenclature is explained in background section, last paragraph. Individual files (.txt extension) can be
viewed with Microsoft Excel or Windows Notepad.
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Figures
Figure 1 - RankGene - Amount of overlap between preprocessing combinations using information gain
ranking criteria on Alzheimer’s disease data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 2 - RankGene - Amount of overlap between preprocessing combinations using twoing rule
ranking criteria on Alzheimer’s disease data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
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Figure 3 - RankGene - Amount of overlap between preprocessing combinations using sum minority
ranking criteria on Alzheimer’s disease data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 4 - RankGene - Amount of overlap between preprocessing combinations using t-statistic
ranking criteria on Alzheimer’s disease data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 5 - Amount of overlap between preprocessing combinations using EDGE on Alzheimer’s disease
data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap. Significant genes are selected on p < 0.01.
Figure 6 - RankGene - Amount of overlap between preprocessing combinations using information gain
ranking criteria on Breast cancer data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 7 - RankGene - Amount of overlap between preprocessing combinations using twoing rule
ranking criteria on Breast cancer data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
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by the degree of overlap.
Figure 8 - RankGene - Amount of overlap between preprocessing combinations using sum minority
ranking criteria on Breast cancer data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 9 - RankGene - Amount of overlap between preprocessing combinations using t-statistic
ranking criteria on Breast cancer data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 10 - Amount of overlap between preprocessing combinations using EDGE on Breast cancer data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap. Significant genes are selected on a p < 0.001.
Figure 11 - RankGene - Amount of overlap between preprocessing combinations using information
gain ranking criteria on chronic myelogenous leukemia data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
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Figure 12 - RankGene - Amount of overlap between preprocessing combinations using twoing rule
ranking criteria on chronic myelogenous leukemia data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 13 - RankGene - Amount of overlap between preprocessing combinations using sum minority
ranking criteria on chronic myelogenous leukemia data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 14 - RankGene - Amount of overlap between preprocessing combinations using t-statistic
ranking criteria on chronic myelogenous leukemia data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 15 - Amount of overlap between preprocessing combinations using EDGE on chronic
myelogenous leukemia data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap. Significant genes are selected on a p < 0.01.
Figure 16 - RankGene - Amount of overlap between preprocessing combinations using information
gain ranking criteria on Duchenne muscular dystrophy data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
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by the degree of overlap.
Figure 17 - RankGene - Amount of overlap between preprocessing combinations using twoing rule
ranking criteria on Duchenne muscular dystrophy data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 18 - RankGene - Amount of overlap between preprocessing combinations using sum minority
ranking criteria on Duchenne muscular dystrophy data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 19 - RankGene - Amount of overlap between preprocessing combinations using t-statistic
ranking criteria on Duchenne muscular dystrophy data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap.
Figure 20 - Amount of overlap between preprocessing combinations using EDGE on Duchenne
muscular dystrophy data
This figure shows the number of common transcripts between two preprocessing combinations. In each of
the eight sets, one stage of the 4-stage preprocessing is changed and the amount of similarity is determined
by the degree of overlap. Significant genes are selected on a p < 0.01.
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Figure 21 - Hierarchical clustering of preprocessing combinations on EDGE selected transcripts on AD
Strength of the similarity is illustrated via colour intensity. Red indicates high similarity and white
indicates no similarity.
Figure 22 - Hierarchical clustering of preprocessing combinations on EDGE selected transcripts on
breast cancer
Strength of the similarity is illustrated via colour intensity. Red indicates high similarity and white
indicates no similarity.
Figure 23 - Hierarchical clustering of preprocessing combinations on EDGE selected transcripts on
CML
Strength of the similarity is illustrated via colour intensity. Red indicates high similarity and white
indicates no similarity.
Figure 24 - Hierarchical clustering of preprocessing combinations on EDGE selected transcripts on
DMD
Strength of the similarity is illustrated via colour intensity. Red indicates high similarity and white
indicates no similarity.
Tables
Table 1 - Processing methods and the stages they were applied in
x refers to the stage the method was applied in. Letters in brackets refer to the abbreviation of that method.
Processing Method Background correction(stage 1) Normalisation(stage 2) PM correction(stage 3) Summarisation(stage 4)
RMA (R) x x x
MAS5.0 (M) x x x
GCRMA (G) x
Constant (C) x
Quantiles (Q) x
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Table 2 - Number of significant transcripts selected by EDGE
Significant transcripts at p < 0.001 for breast cancer and p < 0.01 for all others. The order of preprocessing is first background
correction, then normalisation, followed by PM correction and finally summarisation. These four stages refer to the four letters in
each preprocessing combination in order. R refers to RMA, C refers to constant, Q refers to quantile, M refers to MAS5.0, and G
refers to GCRMA.
Preprocessing Combination AD Breast Cancer CML DMD
RCRR 115 567 110 1370
RQRR 61 966 35 2224
MQRR 41 680 28 2364
RQMM 65 517 37 1631
MCMM 76 1352 52 1821
RCMM 104 573 215 878
MCRR 67 644 17 1682
MQMM 86 476 54 2004
RCRM 99 644 182 1483
RQRM 61 746 18 1885
MQRM 67 573 29 1848
RQMR 44 1194 16 2230
MCMR 66 752 80 1683
RCMR 135 899 136 1057
MCRM 59 672 22 1419
MQMR 56 543 75 2134
GCRM 73 1593 493 1514
GCRR 142 1506 178 1559
GQRM 90 3181 45 2142
GQRR 44 5156 17 2084
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